Al Jnainati Mustafa, Ikkurthy Niharika, Ayoub Mohammad, Shahid Areeba, Baig Mirza Taha, Iltaf Muhammad, Al Jnainati Jana
University of Bologna, Bologna, Italy.
Rollins School of Public Health, Emory University, Atlanta, USA.
Int J Colorectal Dis. 2025 Aug 29;40(1):190. doi: 10.1007/s00384-025-04944-4.
Superior rectal artery embolization ("Emborrhoid") offers a catheter-based alternative for grade I-III internal hemorrhoids when office therapies fail or surgery is undesirable.
Following PRISMA 2020, PubMed and Embase were searched (Jan 2014-Jan 2024). Two reviewers independently screened records, extracted data, and applied RoB 2, ROBINS-I, or an adapted Newcastle-Ottawa Scale. Prespecified outcomes were technical success, clinical success (≥ 2-point fall in bleeding score or equivalent), adverse events, and recurrence. Substantial heterogeneity blocked meta-analysis; results were narratively synthesized.
Twenty-two studies encompassing 810 procedures qualified. Technical success reached 93-100%. Clinical success ranged from 63 to 94%, yielding marked bleeding control and symptom relief. Reported complications were mild and self-limited (pelvic discomfort, nausea, and low-grade fever); no ischemic injury, continence disturbance, or mortality occurred. Recurrence necessitating repeat treatment affected 8-20% of patients, usually when collateral arterial supply persisted. Patient-reported satisfaction exceeded 80% in every series. Only two small, heterogeneous comparative studies versus rubber-band ligation or sclerotherapy were available, precluding a pooled analysis.
Current evidence suggests Emborrhoid is a safe, effective bridge between office procedures and surgery-particularly valuable for frail or anticoagulated patients. Yet small single-center cohorts, disparate techniques, and scarce head-to-head trials limit external validity. Multicenter randomized studies with harmonized outcomes and ≥ 24-month follow-up are required to confirm long-term efficacy, cost-effectiveness, and optimal patient selection.
当门诊治疗失败或患者不愿接受手术时,直肠上动脉栓塞术(“内痔栓塞术”)为I-III度内痔提供了一种基于导管的替代治疗方法。
按照PRISMA 2020的标准,检索了PubMed和Embase数据库(2014年1月至2024年1月)。两名 reviewers 独立筛选记录、提取数据,并应用RoB 2、ROBINS-I或改编的纽卡斯尔-渥太华量表。预先设定的结局指标为技术成功率、临床成功率(出血评分下降≥2分或等效情况)、不良事件和复发率。由于存在实质性异质性,无法进行荟萃分析;结果进行了叙述性综合。
22项研究共纳入810例手术,符合要求。技术成功率达到93%-100%。临床成功率在63%至94%之间,显著控制了出血并缓解了症状。报告的并发症轻微且为自限性(盆腔不适、恶心和低热);未发生缺血性损伤、大便失禁或死亡。需要重复治疗的复发率影响了8%-20%的患者,通常是在侧支动脉供应持续存在的情况下。每个系列中患者报告的满意度均超过80%。仅有两项与橡皮圈套扎术或硬化疗法对比的小型、异质性比较研究,无法进行汇总分析。
目前的证据表明,内痔栓塞术是门诊手术和手术之间安全、有效的桥梁,对体弱或正在接受抗凝治疗的患者尤其有价值。然而,小型单中心队列、不同的技术以及缺乏直接对比试验限制了其外部有效性。需要开展多中心随机研究,统一结局指标并进行≥24个月的随访,以确认其长期疗效、成本效益和最佳患者选择。